Department of Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Department of Molecular Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Front Endocrinol (Lausanne). 2023 Oct 4;14:1270796. doi: 10.3389/fendo.2023.1270796. eCollection 2023.
The American Thyroid Association risk stratification (ATA) and the American Joint Committee on Cancer Tumor Node Metastases (TNM) predict recurrence and mortality of differentiated thyroid cancer (DTC). and promoter mutations have been shown to correlate with the histopathological features and outcome of DTC. Our objectives were to study the correlation of these molecular markers with these clinicopathological-staging systems.
We studied 296 unselected patients, 214 females and 82 males with a median age of 36 years (IQR 23.3-49.0). and promoter mutations were tested by PCR-based Sanger sequencing. Data were extracted from medical records and analysed using Chi-Square and Fisher Exact tests and Kaplan Meier analysis.
Of 296 patients tested, 137 (46.3%) had -positive tumors and 72 (24.3%) were positive for promoter mutations. The mutation did not correlate with the ATA and TNM staging, being non-significantly different in various stages of these systems and did not predict the development of persistent disease (PD) ( 0.12). Unlike , promoter mutations were more frequent in the ATA high-risk than in intermediate- or low-risk tumors (P 0.006) and in TNM stages III and IV than lower stages (0.0001). promoter mutations also predicted the outcome, being present in 37.2% of patients with PD compared to only 15.4% in those without evidence of disease (0.0001). The same pattern was also seen when and promoter mutations were combined.
promoter mutations alone or in combination with mutation, but not mutation alone, correlated well with the ATA and TNM staging and predicted development of PD, especially in higher stages of these systems.
美国甲状腺协会风险分层（ATA）和美国癌症联合委员会肿瘤淋巴结转移（TNM）预测分化型甲状腺癌（DTC）的复发和死亡率。 和 启动子突变已被证明与 DTC 的组织病理学特征和结果相关。我们的目的是研究这些分子标志物与这些临床病理分期系统的相关性。
我们研究了 296 名未经选择的患者，其中 214 名女性和 82 名男性，中位年龄为 36 岁（IQR 23.3-49.0）。 和 启动子突变通过基于 PCR 的 Sanger 测序进行测试。从病历中提取数据，并使用卡方检验和 Fisher 精确检验以及 Kaplan-Meier 分析进行分析。
在 296 名接受测试的患者中，137 名（46.3%）患有 -阳性肿瘤，72 名（24.3%）为 启动子突变阳性。 突变与 ATA 和 TNM 分期不相关，在这些系统的各个阶段均无显著性差异，也不能预测持续性疾病（PD）的发展（0.12）。与 不同， 启动子突变在 ATA 高危组中比在中危或低危组中更为常见（P 0.006），在 TNM 分期 III 和 IV 中比在较低分期中更为常见（0.0001）。 启动子突变也预测了结果，在 PD 患者中存在 37.2%，而在无疾病证据的患者中仅存在 15.4%（0.0001）。当 和 启动子突变联合使用时，也出现了相同的模式。
单独或联合 突变而非 突变与 ATA 和 TNM 分期相关良好，并预测 PD 的发展，尤其是在这些系统的较高分期中。
